首页> 外文期刊>Nature >Structural basis of ligand binding modes at the neuropeptide Y Y_1 receptor
【24h】

Structural basis of ligand binding modes at the neuropeptide Y Y_1 receptor

机译:神经肽Y Y_1受体上配体结合模式的结构基础

获取原文
获取原文并翻译 | 示例
       

摘要

Neuropeptide Y (NPY) receptors belong to the G-protein-coupled receptor superfamily and have important roles in food intake, anxiety and cancer biology(1,2). The NPY-Y receptor system has emerged as one of the most complex networks with three peptide ligands (NPY, peptide YY and pancreatic polypeptide) binding to four receptors in most mammals, namely the Y-1, Y-2, Y-4 and Y-5 receptors, with different affinity and selectivity(3). NPY is the most powerful stimulant of food intake and this effect is primarily mediated by the Y-1 receptor (Y1R)(4). A number of peptides and small-molecule compounds have been characterized as Y1R antagonists and have shown clinical potential in the treatment of obesity(4), tumour(1) and bone loss(5). However, their clinical usage has been hampered by low potency and selectivity, poor brain penetration ability or lack of oral bioavailability(6). Here we report crystal structures of the human Y1R bound to the two selective antagonists UR-MK299 and BMS-193885 at 2.7 and 3.0 angstrom resolution, respectively. The structures combined with mutagenesis studies reveal the binding modes of Y1R to several structurally diverse antagonists and the determinants of ligand selectivity. The Y1R structure and molecular docking of the endogenous agonist NPY, together with nuclear magnetic resonance, photo-crosslinking and functional studies, provide insights into the binding behaviour of the agonist and for the first time, to our knowledge, determine the interaction of its N terminus with the receptor. These insights into Y1R can enable structure-based drug discovery that targets NPY receptors.
机译:神经肽Y(NPY)受体属于G蛋白偶联受体超家族,在食物摄入,焦虑症和癌症生物学中具有重要作用(1,2)。 NPY-Y受体系统已成为最复杂的网络之一,在大多数哺乳动物中,三个肽配体(NPY,YY肽和胰腺多肽)与四个受体结合,即Y-1,Y-2,Y-4和Y-5受体,具有不同的亲和力和选择性(3)。 NPY是食物摄入最有力的刺激物,这种作用主要是由Y-1受体(Y1R)介导的(4)。许多肽和小分子化合物已被表征为Y1R拮抗剂,并已显示出在治疗肥胖症(4),肿瘤(1)和骨质流失(5)中的临床潜力。但是,由于其效力和选择性低,脑渗透能力差或缺乏口服生物利用度,阻碍了它们的临床使用(6)。在这里,我们报告人Y1R的晶体结构分别以2.7和3.0埃的分辨率与两个选择性拮抗剂UR-MK299和BMS-193885结合。结合诱变研究的结构揭示了Y1R与几种结构多样的拮抗剂的结合模式以及配体选择性的决定因素。内源性激动剂NPY的Y1R结构和分子对接,以及核磁共振,光交联和功能研究,提供了对激动剂结合行为的见解,并且据我们所知,这是首次确定其N的相互作用总站与受体。这些对Y1R的洞察力可以实现针对NPY受体的基于结构的药物发现。

著录项

  • 来源
    《Nature》 |2018年第7702期|520-524|共5页
  • 作者单位

    Chinese Acad Sci, Shanghai Inst Mat Medica, Key Lab Receptor Res, Shanghai, Peoples R China;

    Chinese Acad Sci, Shanghai Inst Mat Medica, Key Lab Receptor Res, Shanghai, Peoples R China;

    Univ Regensburg, Inst Pharm, Pharmaceut Med Chem 2, Regensburg, Germany;

    Vanderbilt Univ, Dept Pharmacol, Struct Biol Ctr, Nashville, TN USA;

    Univ Leipzig, Inst Med Phys & Biophys, Leipzig, Germany;

    Univ Leipzig, Inst Biochem, Fac Life Sci, Leipzig, Germany;

    Univ Leipzig, Inst Biochem, Fac Life Sci, Leipzig, Germany;

    Univ Regensburg, Inst Pharm, Pharmaceut Med Chem 2, Regensburg, Germany;

    Univ Regensburg, Inst Pharm, Pharmaceut Med Chem 2, Regensburg, Germany;

    Univ Regensburg, Inst Pharm, Pharmaceut Med Chem 2, Regensburg, Germany;

    Univ Regensburg, Inst Pharm, Pharmaceut Med Chem 2, Regensburg, Germany;

    Univ Leipzig, Inst Med Phys & Biophys, Leipzig, Germany;

    Chinese Acad Sci, Shanghai Inst Mat Medica, Key Lab Receptor Res, Shanghai, Peoples R China;

    Chinese Acad Sci, Shanghai Inst Mat Medica, Key Lab Receptor Res, Shanghai, Peoples R China;

    Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing, Peoples R China;

    Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing, Peoples R China;

    Uppsala Univ, Sci Life Lab, Dept Neurosci, Uppsala, Sweden;

    Uppsala Univ, Sci Life Lab, Dept Neurosci, Uppsala, Sweden;

    ShanghaiTech Univ, Human Inst, Shanghai, Peoples R China;

    Univ Leipzig, Inst Med Phys & Biophys, Leipzig, Germany;

    Vanderbilt Univ, Dept Pharmacol, Struct Biol Ctr, Nashville, TN USA;

    Chinese Acad Sci, Shanghai Inst Mat Medica, Key Lab Receptor Res, Shanghai, Peoples R China;

    Univ Leipzig, Inst Biochem, Fac Life Sci, Leipzig, Germany;

    Univ Regensburg, Inst Pharm, Pharmaceut Med Chem 2, Regensburg, Germany;

    Chinese Acad Sci, Shanghai Inst Mat Medica, Key Lab Receptor Res, Shanghai, Peoples R China;

  • 收录信息 美国《科学引文索引》(SCI);美国《工程索引》(EI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号